vs
Side-by-side financial comparison of GAXOS.AI INC. (GXAI) and RELMADA THERAPEUTICS, INC. (RLMD). Click either name above to swap in a different company.
RELMADA THERAPEUTICS, INC. is the larger business by last-quarter revenue ($1.3M vs $1.2M, roughly 1.0× GAXOS.AI INC.). On growth, GAXOS.AI INC. posted the faster year-over-year revenue change (94996.3% vs 13.0%).
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies for central nervous system disorders. Its lead product candidate targets treatment-resistant depression, with ongoing clinical trials to address unmet medical needs in its primary markets of North America and Europe.
GXAI vs RLMD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $1.3M |
| Net Profit | $-957.9K | — |
| Gross Margin | — | — |
| Operating Margin | -99.0% | -2130.6% |
| Net Margin | -77.2% | — |
| Revenue YoY | 94996.3% | 13.0% |
| Net Profit YoY | -15.1% | — |
| EPS (diluted) | $-0.13 | $-0.84 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2M | — | ||
| Q3 25 | $498.3K | — | ||
| Q2 25 | $171.0K | — | ||
| Q2 24 | $0 | — | ||
| Q4 23 | — | $1.3M | ||
| Q3 23 | — | $1.3M | ||
| Q2 23 | — | $1.4M | ||
| Q1 23 | — | $1.2M |
| Q4 25 | $-957.9K | — | ||
| Q3 25 | $-1.0M | — | ||
| Q2 25 | $-749.4K | — | ||
| Q2 24 | $-809.2K | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | $-22.0M | ||
| Q2 23 | — | $-25.3M | ||
| Q1 23 | — | $-26.3M |
| Q4 25 | -99.0% | — | ||
| Q3 25 | -263.9% | — | ||
| Q2 25 | -574.8% | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | -2130.6% | ||
| Q3 23 | — | -1717.3% | ||
| Q2 23 | — | -1908.9% | ||
| Q1 23 | — | -2331.3% |
| Q4 25 | -77.2% | — | ||
| Q3 25 | -201.0% | — | ||
| Q2 25 | -438.3% | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | -1665.0% | ||
| Q2 23 | — | -1855.9% | ||
| Q1 23 | — | -2179.6% |
| Q4 25 | $-0.13 | — | ||
| Q3 25 | $-0.14 | — | ||
| Q2 25 | $-0.11 | — | ||
| Q2 24 | $-0.72 | — | ||
| Q4 23 | — | $-0.84 | ||
| Q3 23 | — | $-0.73 | ||
| Q2 23 | — | $-0.84 | ||
| Q1 23 | — | $-0.87 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $840.5K | $96.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $13.1M | $85.4M |
| Total Assets | $13.4M | $97.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $840.5K | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | $4.5M | — | ||
| Q4 23 | — | $96.3M | ||
| Q3 23 | — | $106.3M | ||
| Q2 23 | — | $118.5M | ||
| Q1 23 | — | $132.4M |
| Q4 25 | $13.1M | — | ||
| Q3 25 | $14.1M | — | ||
| Q2 25 | $15.0M | — | ||
| Q2 24 | $4.7M | — | ||
| Q4 23 | — | $85.4M | ||
| Q3 23 | — | $100.7M | ||
| Q2 23 | — | $111.3M | ||
| Q1 23 | — | $125.5M |
| Q4 25 | $13.4M | — | ||
| Q3 25 | $14.3M | — | ||
| Q2 25 | $15.4M | — | ||
| Q2 24 | $5.1M | — | ||
| Q4 23 | — | $97.6M | ||
| Q3 23 | — | $109.1M | ||
| Q2 23 | — | $122.0M | ||
| Q1 23 | — | $135.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-733.1K | $-10.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-733.1K | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $-716.9K | — | ||
| Q2 24 | $-738.5K | — | ||
| Q4 23 | — | $-10.2M | ||
| Q3 23 | — | $-11.6M | ||
| Q2 23 | — | $-13.3M | ||
| Q1 23 | — | $-16.5M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
